- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04532645
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK (OVAL-1)
October 9, 2023 updated by: AstraZeneca
A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK.
Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws
Study Overview
Detailed Description
Primary Objective(s)
- To estimate progression-free survival (PFS) in patients with BRCA-mutated advanced ovarian cancer treated with olaparib tablets in real-world first line maintenance setting.
- To describe olaparib treatment patterns (dosage; frequency of: dosage changes, dose interruptions, treatment cessation) in patients with BRCA-mutated advanced ovarian cancer treated in real-world first line maintenance setting.
Secondary Objective(s)
- To estimate overall survival (OS) in patients with BRCA-mutated advanced ovarian cancer treated with olaparib tablets in real-world first line maintenance setting.
- To describe reasons for olaparib dosage changes, dose interruptions and treatment cessation in patients with BRCA-mutated advanced ovarian cancer treated in real-world first line maintenance setting
- To describe surgical and chemotherapy outcomes (PR/CR) in patients with BRCA-mutated advanced ovarian cancer before initiation of real-world first line maintenance olaparib tablets
- To describe response rate (RR) to olaparib tablets in patients with BRCA-mutated ovarian cancer with partial response to real-world first line chemotherapy.
- To describe treatment patterns and clinical outcomes in patients with BRCA-mutated advanced ovarian cancer who progressed during olaparib real-world first line maintenance therapy (including frequency of treatment interruptions, dosage reductions and treatment discontinuations and reasons associated with patterns)
- To estimate second progression-free survival (PFS2) in patients with BRCA-mutated ovarian cancer who progress while on olaparib real-world first line maintenance therapy.
- To describe healthcare resource utilisation in patients with BRCA-mutated advanced ovarian cancer treated with olaparib in real-world first line setting
Study Type
Observational
Enrollment (Estimated)
350
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Avignon, France, 84918
- Research Site
-
Besancon, France
- Research Site
-
Bordeaux, France
- Research Site
-
Bordeaux, France, 33000
- Research Site
-
Bourg-en-Bresse, France, 01012
- Research Site
-
Brest, France, 29200
- Research Site
-
Calais, France, 62100
- Research Site
-
Chalon-sur-Saone, France, 71321
- Research Site
-
Chambray-les-Tours, France
- Research Site
-
Dijon, France, 21000
- Research Site
-
Epagny Metz-Tessy, France
- Research Site
-
Grenoble, France, 38000
- Research Site
-
Langon, France, 33210
- Research Site
-
Le Coudray, France
- Research Site
-
Lille, France, 59000
- Research Site
-
Lille, France
- Research Site
-
Limoges, France, 87000
- Research Site
-
Lyon, France
- Research Site
-
Marseille, France, 13009
- Research Site
-
Nancy, France
- Research Site
-
Paris, France
- Research Site
-
Paris, France, 75014
- Research Site
-
Paris, France, 75960
- Research Site
-
Pierre-Benite, France
- Research Site
-
Pontoise, France, 95300
- Research Site
-
Rennes, France
- Research Site
-
Roubaix, France
- Research Site
-
Saint-Cloud, France
- Research Site
-
Saint-Gregoire, France, 35760
- Research Site
-
Sainte Clotilde - La Reunion, France
- Research Site
-
Strasbourg, France
- Research Site
-
Suresnes, France
- Research Site
-
Tours, France, 37000
- Research Site
-
Valenciennes, France, 59300
- Research Site
-
Vandoeuvre-les-Nancy, France, 54519
- Research Site
-
Villejuif, France
- Research Site
-
-
La Réunion (oversea France)
-
Saint Pierre, La Réunion (oversea France), France, 97410
- Research Site
-
-
-
-
-
Edinburgh, United Kingdom
- Research Site
-
Glasgow, United Kingdom
- Research Site
-
Leeds, United Kingdom
- Research Site
-
Liverpool, United Kingdom
- Research Site
-
London, United Kingdom, SW36JJ
- Research Site
-
London, United Kingdom, EC1A7BE
- Research Site
-
London, United Kingdom, NW12BU
- Research Site
-
London, United Kingdom, W120HS
- Research Site
-
Maidstone, United Kingdom
- Research Site
-
Manchester, United Kingdom
- Research Site
-
Newcastle, United Kingdom
- Research Site
-
Nottingham, United Kingdom
- Research Site
-
Portsmouth, United Kingdom
- Research Site
-
Surrey, United Kingdom
- Research Site
-
Swansea, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
• Patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer treated with olaparib in first-line maintenance setting
Description
Inclusion Criteria:
- Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have completed first line platinum-based chemotherapy, in PR/CR and treated with at least one dose of olaparib in first line maintenance setting
- Patients aged ≥18 years old
- Ability and/or willingness to provide a signed informed consent form (where required)
Exclusion Criteria:
- Withdrawal of informed consent (where consent required)
- Concurrent participation in any clinical study with an investigational product at the time of olaparib initiation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with BRCA mutated ovarian cancer
BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
|
Olaparib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression
Time Frame: 36 months
|
Progression-free survival (PFS)
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 36 months
|
Overall survival over 36 months
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charlie Gourley, MD, PhD, University of Edinburgh
- Principal Investigator: Domenica Lorusso, MD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Principal Investigator: Delphine Garbay, MD, Institut Bergonie, France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2020
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
August 26, 2020
First Submitted That Met QC Criteria
August 26, 2020
First Posted (Actual)
August 31, 2020
Study Record Updates
Last Update Posted (Actual)
October 10, 2023
Last Update Submitted That Met QC Criteria
October 9, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Olaparib
Other Study ID Numbers
- D0817R00019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Supporting Information Type
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovary Cancer
-
Health Science Center of Xi'an Jiaotong UniversityRecruitingOvarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, OvarianChina
-
Washington University School of MedicineCompletedOvarian Cancer | Cancer of the Ovary | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Cancer of OvaryUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); University of Pittsburgh; AIM ImmunoTech Inc.SuspendedOvarian Cancer | Cancer of the Ovary | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Cancer of OvaryUnited States
-
South Plains Oncology ConsortiumTerminatedOvarian Cancer | Cancer of the Ovary | Primary Peritoneal Carcinoma | Ovary Neoplasms | Cancer of OvaryUnited States
-
Ain Shams UniversityUnknown
-
Nuvation Bio Inc.RecruitingBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditionsUnited States, Australia
-
Memorial Sloan Kettering Cancer CenterRecruitingOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditionsUnited States
-
Parc de Salut MarCompleted
-
Faculdade de Ciências Médicas da Santa Casa de...Federal University of Paraíba; Irmandade da Santa Casa de Misericordia de Sao...Active, not recruitingLaparoscopy | Hemostasis | Endometriosis Ovary | Ovary; Functional DisturbanceBrazil
-
University of Texas Southwestern Medical CenterAstraZenecaTerminatedFallopian Tube Cancer | Primary Peritoneal Carcinoma | Recurrent Epithelial Cancer of OvaryUnited States
Clinical Trials on Olaparib
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
SandozCompleted
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm EpithelialNetherlands